Immunovant reported a net loss of $110.6 million, or $0.61 per share, for the three months ended December 31 2025, a modest improvement from the $111.1 million loss ($0.76 per share) reported a year earlier. The company’s earnings per share beat the consensus estimate of $-0.72 by $0.11, reflecting tighter cost control amid increased research spending.
Research and development costs rose to $98.9 million, up 4.4 % from $94.5 million a year earlier. The increase was driven by higher contract manufacturing and personnel expenses for the IMVT‑1402 clinical program, partially offset by lower costs associated with batoclimab trials. General and administrative expenses fell to $15.4 million from $19.8 million, a 22 % reduction largely due to lower personnel, market‑research, and information‑technology costs.
Cash and cash equivalents stood at $994.5 million as of December 31 2025. The liquidity position, bolstered by a recent $550 million financing round, provides a runway that extends through the anticipated Graves’ disease readout in 2027, giving the company time to advance its flagship IMVT‑1402 program.
The market reacted positively to the earnings, with analysts noting the EPS beat and the company’s strong cash position as key drivers of confidence. Management emphasized continued focus on the IMVT‑1402 pipeline and the strategic importance of the recent financing in extending the cash runway.
Immunovant’s leadership highlighted that the company remains committed to advancing its pipeline across multiple autoimmune indications, with top‑line data expected from rheumatoid arthritis and cutaneous lupus erythematosus trials in the second half of 2026 and from Graves’ disease and myasthenia gravis trials in 2027. The company’s financial results and cash position reinforce its ability to fund these milestones without immediate additional capital raises.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.